Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer-a randomized biomarker pilot study

Clinical Cancer Research

Volumn 19, Issue 10, 2013, Pages 2755-2765

  Winter, Matthew C ^a,d   Wilson, Caroline ^a   Syddall, Stuart P ^a   Cross, Simon S ^b   Evans, Alyson ^a   Ingram, Christine E ^e   Jolley, Ingrid J ^e   Hatton, Matthew Q ^a   Freeman, Jennifer V ^c   Mori, Stefano ^a   Holen, Ingunn ^a   Coleman, Robert E ^a,d  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b Academic Unit of Haematology   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; FOLLISTATIN; INHIBIN A; KI 67 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; TRASTUZUMAB; VASCULOTROPIN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; INHIBIN; TAXOID; VASCULOTROPIN A;

ADULT; APOPTOSIS; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EARLY CANCER; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; MENOPAUSE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PILOT STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; ADJUVANT THERAPY; BLOOD; BREAST NEOPLASMS; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLISTATIN; HUMANS; IMIDAZOLES; INHIBINS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PILOT PROJECTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TAXOIDS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84878038828     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3235     Document Type: Article

References (30)

1. Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone 2011;49:71-6.
2. Coleman RE, Gnant M, Morgan G, Clezardin P. Effects of bonetargeted agents on cancer progression and mortality. J Natl Cancer Inst 2012;104:1059-67.
3. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008;34: 453-75.
4. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008;100:1167-78.
5. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 2009;8:2821-32.
6. Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 2010;126:522-532.
7. Ottewell PD, Brown HK, Jones M, Rogers TL, Cross SS, Brown NJ, et al. Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice. Breast Cancer Res Treat 2011;133:523-36.
8. de Boer R, Bundred N, Eidtmann H, Neven P, von Minckwitz G, Martin N, et al. Long-term survival outcome among post-menopausal women with hormone receptor-positive early breast cancer receiving adjuvant letrozole and zoledronic acid; 5-year follow-up of ZO-FAST [abstract]. In: Proceedings of the Thirty-Fourth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2011 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; 2011. Abstract nr S1-S3.
9. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-91.
10. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011;365:1396-405.
11. Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012;13:734-42.
12. Hadji P, Coleman R, Gnant M, Green J. The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. Ann Oncol 2012;23:2782-2790.
13. Wilson C, Holen I, Coleman RE. Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. Cancer Treat Rev 2012;38:877-89.
14. Korpal M, Yan J, Lu X, Xu S, Lerit DA, Kang Y. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 2009;15:960-6.
15. Sakai R, Eto Y, Hirafuji M, Shinoda H. Activin release from bone coupled to bone resorption in organ culture of neonatal mouse calvaria. Bone 2000;26:235-40.
16. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct antitumour activity in breast cancer. Br J Cancer 2010;102:1099-105.
17. Gallo M, De Luca A, Lamura L, Normanno N. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol 2011;23:597-604.
18. Archer CD, Parton M, Smith IE, Ellis PA, Salter J, Ashley S, et al. Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 2003;89:1035-1041.
19. Arpino G, Ciocca DR, Weiss H, Allred DC, Daguerre P, Vargas-Roig L, et al. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase II alpha for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 2005;92: 69-75.
20. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000;89:2145-52.
21. Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res 2003;9:955-960.
22. Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M. Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet 1997;349:849.
23. Weiss HM, Pfaar U, Schweitzer A, Wiegand H, Skerjanec A, Schran H. Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 2008;36:2043-9.
24. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-25.
25. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997;3:2187-90.
26. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007;13:4482-6.
27. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97:3658-61.
28. Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 2006;94:524-31.
29. Hasmim M, Bieler G, Ruegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost 2007;5:166-73.
30. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004;114:623-33.